- Title: Subtitle
- Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma
- Creators
- Yousef Zakharia - University of IowaJoseph J. Drabick - Penn State Milton S. Hershey Medical CenterSamir Khleif - Augusta UniversityRobert R. McWilliams - Mayo Clinic Rochester, MNDavid Munn - Augusta UniversityCharles J. Link - NewLink GeneticsNicholas N. Vahanian - NewLink GeneticsEugene Kennedy - NewLink GeneticsMontaser F. Shaheen - New Mexico Cancer CenterOlivier Rixe - New Mexico Cancer CenterMohammed M. Milhem - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.3075-3075
- DOI
- 10.1200/JCO.2016.34.15_suppl.3075
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363180802771
Abstract
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma
Journal of clinical oncology, Vol.34(15_suppl), pp.3075-3075
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.3075
Details
Metrics
8 Record Views